重组抗人CD20单抗(2H7) | Syd Labs PA007455
体内实验级重组抗人CD20单克隆抗体，小鼠IgG2b Kappa（克隆号：2H7，Syd Labs货号：PA007455）是用哺乳动物细胞生产的重组抗体，适用于体外和体内研究，纯度>95%。其不变区为小鼠Mouse IgG2b Kappa (mIgG2b或m2b)，可与重组小鼠IgG2b同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007455 |
|---|---|
| 产品名称 | 重组抗人CD20单抗(2H7) | Syd Labs PA007455 |
| 英文名 | In vivo Grade Recombinant Anti-Human CD20 Monoclonal Antibody, Mouse IgG2b Kappa (Clone: 2H7) |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | B 淋巴细胞抗原 CD20、B 淋巴细胞表面抗原 B1、Bp35、白细胞表面抗原 Leu-16、跨膜 4 结构域亚家族 A 成员 1、CD 抗原 CD20、CD20 |
| 概述 | Syd Labs提供重组小鼠IgG2b同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 2H7 |
| 同种型 | 小鼠 IgG2b kappa |
| 应用 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人CD20蛋白影响的生物途径的测定。 |
| 免疫源 | 重组抗人CD20单克隆抗体（克隆：2H7）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2 μM过滤溶液，1x PBS |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人CD20单克隆抗体，小鼠IgG2b Kappa(克隆号2H7) 用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007455 Syd Labs提供重组小鼠IgG2b同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人CD20蛋白影响的生物途径的测定。 |
文献
抗人CD20单克隆抗体 ，体内实验级重组，小鼠IgG2b Kappa(克隆号2H7)（In vivo Grade Recombinant Anti-Human CD20 Monoclonal Antibody, Mouse IgG2b Kappa (Clone: 2H7)，货号：PA007455 Syd Labs）
抗人CD20单抗（克隆号2H7）是淋巴细胞生物学与免疫学研究中经典的B细胞靶向工具。CD20作为表达于前B细胞至成熟B细胞表面的四次跨膜非糖基化蛋白，在调控B细胞跨膜钙离子流、细胞激活、增殖及分化中发挥核心作用。2H7抗体能够特异性结合人CD20胞外环区，常用于诱导抗体依赖性细胞介导的细胞毒性（ADCC）与补体依赖性细胞毒性（CDC）、介导体外及体内B细胞耗竭，以及评估自身免疫性疾病与B细胞来源肿瘤的免疫干预效果。
Syd Labs提供的重组抗人CD20单抗（2H7，Mouse IgG2b Kappa，体内实验级）采用高表达哺乳动物细胞系统重组生产，彻底克服了传统杂交瘤表达易发生变异、批间差大及夹杂内源性杂质蛋白的缺陷。产品具备极高的蛋白纯度与良好的批间稳定性，严格控制内毒素水平，且无添加防腐剂及载体蛋白，非常适合敏感的体内（in vivo）和体外（in vitro）功能性实验。此外，该抗体可与Syd Labs重组Mouse IgG2b同型对照抗体配套使用，为生物医药研发与B细胞免疫学研究提供科学严谨、高重复性的可靠数据支撑。
抗人CD20单抗(2H7)部分引用文献:
1. Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes
Hu, C., et al. Diabetes. 2013 Aug;62(8):2849-58. PMID: 23447122
“Thus, the findings demonstrate that combining anti-CD20 and oral anti-CD3 is superior to anti-CD20 monotherapy for restoring normoglycemia in diabetic NOD mice, providing important preclinical evidence for the optimization of B cell-directed therapy for T1D. …Thus, we tested the effect of intravenous anti-CD20 and oral anti-CD3 combined treatment for the prevention and reversal of T1D in the human CD20 transgenic NOD (hCD20/NOD) animal model. …Herein, we show that oral administration of anti-CD3 together with intravenous injection of anti-CD20 has a synergistic effect on the prevention and reversal of T1D in the hCD20/NOD mouse. …All fluorochrome-conjugated monoclonal antibodies (mAbs) were purchased from BioLegend, Inc. Affinity-purified mouse anti-hCD20 mAb 2H7 was prepared by Bio X Cell. …To further improve the efficacy of treatment, we tested the combination treatment of anti-hCD20/oral anti-CD3 in hCD20/NOD mice.”
Hu, C., et al. Diabetes. 2013 Aug;62(8):2849-58. PMID: 23447122
“Thus, the findings demonstrate that combining anti-CD20 and oral anti-CD3 is superior to anti-CD20 monotherapy for restoring normoglycemia in diabetic NOD mice, providing important preclinical evidence for the optimization of B cell-directed therapy for T1D. …Thus, we tested the effect of intravenous anti-CD20 and oral anti-CD3 combined treatment for the prevention and reversal of T1D in the human CD20 transgenic NOD (hCD20/NOD) animal model. …Herein, we show that oral administration of anti-CD3 together with intravenous injection of anti-CD20 has a synergistic effect on the prevention and reversal of T1D in the hCD20/NOD mouse. …All fluorochrome-conjugated monoclonal antibodies (mAbs) were purchased from BioLegend, Inc. Affinity-purified mouse anti-hCD20 mAb 2H7 was prepared by Bio X Cell. …To further improve the efficacy of treatment, we tested the combination treatment of anti-hCD20/oral anti-CD3 in hCD20/NOD mice.”
2. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging
Keren, Z., et al. Blood. 2011 Mar 17;117(11):3104-12. PMID: 21228330
“Mice used were C57Bl6 mice that are normal, or carrying a targeted conditional Baff-r locus (BAFF-RFL),25 transgenic for Mx-cre,26 R26R-EYFP transgene for the EYFP-Cre reporter system,27 or Balb/c transgenic for human CD20 (hCD20 Tg). …An “old-like” B-cell phenotype in C57Bl6 mice and the hCD20Tg mice was determined when the frequency of newly generated AA4.1-expressing B cells in peripheral blood was less than 5% of the B220+ cells. …To deplete B cells in the hCD20 Tg model, mice were injected intraperitoneally with 1 mg/mouse of mouse anti-human CD20 monoclonal antibodies (clone 2H7) as described. …To do so, we used transgenic mice expressing human CD20 specifically in the B lineage (hCD20 Tg mice), starting from the late pre-B stage. …After B-cell depletion, complete B-cell reconstitution in hCD20 Tg mice lasted 60 to 70 days, as described.”
Keren, Z., et al. Blood. 2011 Mar 17;117(11):3104-12. PMID: 21228330
“Mice used were C57Bl6 mice that are normal, or carrying a targeted conditional Baff-r locus (BAFF-RFL),25 transgenic for Mx-cre,26 R26R-EYFP transgene for the EYFP-Cre reporter system,27 or Balb/c transgenic for human CD20 (hCD20 Tg). …An “old-like” B-cell phenotype in C57Bl6 mice and the hCD20Tg mice was determined when the frequency of newly generated AA4.1-expressing B cells in peripheral blood was less than 5% of the B220+ cells. …To deplete B cells in the hCD20 Tg model, mice were injected intraperitoneally with 1 mg/mouse of mouse anti-human CD20 monoclonal antibodies (clone 2H7) as described. …To do so, we used transgenic mice expressing human CD20 specifically in the B lineage (hCD20 Tg mice), starting from the late pre-B stage. …After B-cell depletion, complete B-cell reconstitution in hCD20 Tg mice lasted 60 to 70 days, as described.”
3. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure
Polyak, M. J., et al. Blood. 2002 May 1;99(9):3256-62. PMID: 11964291
“CD20, a nonglycosylated 33- to 35-kd integral membrane protein expressed at high density only on B lymphocytes, has proven to be an effective target for immunotherapeutic removal of malignant B cells. …It is generally assumed, based on antibody blocking studies,5 that CD20 bears only 2 extracellular epitopes, one that is recognized by the vast majority of CD20 mAbs, and a second that is recognized by a single antibody (1F5) with unusual activating properties. …Other CD20 mAbs were obtained from the human leukocyte differentiation workshops IV, VI, and VII. …CD20 translocation experiments were performed as described.14 Briefly, cells were treated before lysis with anti-CD20 mAbs for 15 minutes at 37°C and both the cleared lysates and the insoluble pellets were collected for analysis by CD20 immunoblotting. …Equal aliquots of each fraction were mixed with SDS sample buffer. Western blot analysis and Coomassie staining were used to identify the fractions containing CD20 and the molecular weight standards, respectively.”
Polyak, M. J., et al. Blood. 2002 May 1;99(9):3256-62. PMID: 11964291
“CD20, a nonglycosylated 33- to 35-kd integral membrane protein expressed at high density only on B lymphocytes, has proven to be an effective target for immunotherapeutic removal of malignant B cells. …It is generally assumed, based on antibody blocking studies,5 that CD20 bears only 2 extracellular epitopes, one that is recognized by the vast majority of CD20 mAbs, and a second that is recognized by a single antibody (1F5) with unusual activating properties. …Other CD20 mAbs were obtained from the human leukocyte differentiation workshops IV, VI, and VII. …CD20 translocation experiments were performed as described.14 Briefly, cells were treated before lysis with anti-CD20 mAbs for 15 minutes at 37°C and both the cleared lysates and the insoluble pellets were collected for analysis by CD20 immunoblotting. …Equal aliquots of each fraction were mixed with SDS sample buffer. Western blot analysis and Coomassie staining were used to identify the fractions containing CD20 and the molecular weight standards, respectively.”